NASDAQ:EYES - Second Sight Medical Stock Price, Price Target & More

$1.63 -0.01 (-0.61 %)
(As of 04/26/2018 01:24 PM ET)
Previous Close$1.64
Today's Range$1.60 - $1.69
52-Week Range$0.90 - $2.58
Volume74,916 shs
Average Volume546,200 shs
Market Capitalization$101.79 million
P/E Ratio-2.81
Dividend YieldN/A
Beta3.04

About Second Sight Medical (NASDAQ:EYES)

Second Sight Medical logoSecond Sight Medical Products, Inc., together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa. The company was formerly known as Second Sight LLC. and changed its name to Second Sight Medical Products, Inc. Second Sight Medical Products, Inc. was founded in 1998 and is headquartered in Sylmar, California.

Receive EYES News and Ratings via Email

Sign-up to receive the latest news and ratings for EYES and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EYES
CUSIPN/A
Phone818-833-5000

Debt

Debt-to-Equity RatioN/A
Current Ratio1.99%
Quick Ratio1.58%

Price-To-Earnings

Trailing P/E Ratio-2.81
Forward P/E Ratio-2.81
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.96 million
Price / Sales12.26
Cash FlowN/A
Price / CashN/A
Book Value$0.14 per share
Price / Book11.64

Profitability

EPS (Most Recent Fiscal Year)($0.59)
Net Income$-28,510,000.00
Net Margins-358.06%
Return on Equity-197.61%
Return on Assets-143.82%

Miscellaneous

Employees112
Outstanding Shares59,880,000

How to Become a New Pot Stock Millionaire

Second Sight Medical (NASDAQ:EYES) Frequently Asked Questions

What is Second Sight Medical's stock symbol?

Second Sight Medical trades on the NASDAQ under the ticker symbol "EYES."

How were Second Sight Medical's earnings last quarter?

Second Sight Medical (NASDAQ:EYES) announced its quarterly earnings results on Wednesday, March, 7th. The medical device company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.14) by $0.01. The medical device company earned $3.10 million during the quarter, compared to the consensus estimate of $1.98 million. Second Sight Medical had a negative return on equity of 197.61% and a negative net margin of 358.06%. The firm's quarterly revenue was up 333.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.24) earnings per share. View Second Sight Medical's Earnings History.

When is Second Sight Medical's next earnings date?

Second Sight Medical is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Second Sight Medical.

What price target have analysts set for EYES?

1 brokers have issued twelve-month price targets for Second Sight Medical's stock. Their predictions range from $5.00 to $5.00. On average, they anticipate Second Sight Medical's stock price to reach $5.00 in the next twelve months. View Analyst Ratings for Second Sight Medical.

What are Wall Street analysts saying about Second Sight Medical stock?

Here are some recent quotes from research analysts about Second Sight Medical stock:
  • 1. According to Zacks Investment Research, "Second Sight Medical Products, Inc. is a medical device company. It develops, manufactures, and markets implantable prosthetic devices to restore some functional vision to blind patients. The Company provides Argus II system, an implantable neurostimulation device for the treatment of outer retinal degenerations, such as retinitis pigmentosa. Second Sight Medical Products, Inc. is headquartered in Sylmar, California. " (1/8/2018)
  • 2. HC Wainwright analysts commented, "We expect that the second pilot study could start in late 3Q17 or early 4Q17 and report top-line data by the end of 2017. Investors may recall that this second pilot study is double-masked and slated to enroll up to 45 subjects. The primary endpoint is the percentage of subjects achieving complete wound healing (based on staining) on day 3. Assuming that the second pilot study shows OBG’s ability to heal corneal defects faster than the standard of care, as was seen in the first pilot study, we believe that EyeGate may only need to conduct a single pivotal study in 2018 before filing for regulatory approval. We note that the FDA has permitted EyeGate to pursue U.S. regulatory clearance for OBG through the de novo 510(k) pathway." (8/8/2017)

Who are some of Second Sight Medical's key competitors?

Who are Second Sight Medical's key executives?

Second Sight Medical's management team includes the folowing people:
  • Mr. Jonathan Will McGuire, Chief Exec. Officer, Pres and Director (Age 55)
  • Mr. Edward David Randolph, VP of Manufacturing (Age 60)
  • Mr. Stephen D. Okland Jr., Commercial VP for US & Canada (Age 54)
  • Gunnar Bjorg, Founder

When did Second Sight Medical IPO?

(EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC acted as the underwriter for the IPO.

Has Second Sight Medical been receiving favorable news coverage?

Media headlines about EYES stock have trended somewhat negative recently, according to Accern Sentiment Analysis. The research firm rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Second Sight Medical earned a news sentiment score of -0.10 on Accern's scale. They also gave headlines about the medical device company an impact score of 47.60 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Second Sight Medical?

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Second Sight Medical's stock price today?

One share of EYES stock can currently be purchased for approximately $1.63.

How big of a company is Second Sight Medical?

Second Sight Medical has a market capitalization of $101.79 million and generates $7.96 million in revenue each year. The medical device company earns $-28,510,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. Second Sight Medical employs 112 workers across the globe.

How can I contact Second Sight Medical?

Second Sight Medical's mailing address is 12744 SAN FERNANDO ROAD BLDG. 3, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]


MarketBeat Community Rating for Second Sight Medical (EYES)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  244
MarketBeat's community ratings are surveys of what our community members think about Second Sight Medical and other stocks. Vote "Outperform" if you believe EYES will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYES will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Second Sight Medical (NASDAQ:EYES) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Second Sight Medical in the last 12 months. Their average twelve-month price target is $5.00, suggesting that the stock has a possible upside of 206.75%. The high price target for EYES is $5.00 and the low price target for EYES is $5.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.00$5.00$5.00$5.00
Price Target Upside: 206.75% upside116.45% upside339.44% upside342.48% upside

Second Sight Medical (NASDAQ:EYES) Consensus Price Target History

Price Target History for Second Sight Medical (NASDAQ:EYES)

Second Sight Medical (NASDAQ:EYES) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/5/2018HC WainwrightSet Price TargetBuy$5.00HighView Rating Details
7/26/2016Rodman & RenshawReiterated RatingBuy$16.00N/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Second Sight Medical (NASDAQ:EYES) Earnings History and Estimates Chart

Earnings by Quarter for Second Sight Medical (NASDAQ:EYES)

Second Sight Medical (NASDAQ:EYES) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.58 EPS
Next Year EPS Consensus Estimate: $-0.51 EPS

Second Sight Medical (NASDAQ EYES) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018N/AView Earnings Details
3/7/2018Q4 2017($0.14)($0.13)$1.98 million$3.10 millionViewN/AView Earnings Details
11/2/2017Q3 2017($0.14)($0.12)$1.54 million$1.61 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.14)($0.13)$1.43 million$2.24 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.14)($0.18)$1.32 million$1.01 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.17)($0.24)$1.76 million$0.72 millionViewListenView Earnings Details
11/2/2016Q316($0.16)($0.15)$2.36 million$1.20 millionViewN/AView Earnings Details
7/28/2016Q216($0.15)($0.17)$2.66 million$1.04 millionViewListenView Earnings Details
4/28/2016Q116($0.16)($0.13)$1.38 million$1.05 millionViewListenView Earnings Details
3/3/2016Q415($0.14)($0.15)$2.47 million$2.40 millionViewN/AView Earnings Details
10/29/2015Q315($0.14)($0.13)$2.05 million$2.23 millionViewListenView Earnings Details
8/4/2015Q215($0.14)($0.14)$1.73 million$2.70 millionViewN/AView Earnings Details
5/13/2015Q115($0.12)$1.70 millionViewListenView Earnings Details
3/11/2015Q4 2014($0.18)$1.52 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Second Sight Medical (NASDAQ:EYES) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Second Sight Medical (NASDAQ EYES) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 34.70%
Institutional Ownership Percentage: 12.77%
Insider Trading History for Second Sight Medical (NASDAQ:EYES)
Institutional Ownership by Quarter for Second Sight Medical (NASDAQ:EYES)

Second Sight Medical (NASDAQ EYES) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/20/2017Gregg WilliamsDirectorBuy17,020$1.18$20,083.60View SEC Filing  
11/17/2017Gregg WilliamsDirectorBuy5,420$1.17$6,341.40View SEC Filing  
4/7/2017Gregg WilliamsDirectorBuy4,000,000$1.00$4,000,000.00View SEC Filing  
12/1/2016Robert J GreenbergChairmanSell1,950$1.96$3,822.00172,911View SEC Filing  
6/3/2016Edward David RandolphVPSell5,104$4.01$20,467.04View SEC Filing  
6/2/2016Robert J GreenbergChairmanSell8,571$4.10$35,141.10172,911View SEC Filing  
4/18/2016Robert J GreenbergChairmanSell8,223$5.27$43,335.21181,134View SEC Filing  
12/7/2015Robert J. GreenbergChairmanSell17,969$5.30$95,235.70172,911View SEC Filing  
12/4/2015Anne-Marie Juliette RipleyVPSell2,500$5.50$13,750.00View SEC Filing  
6/4/2015Anne-Marie Juliette RipleyVPSell4,371$15.00$65,565.00View SEC Filing  
6/3/2015Robert J GreenbergCEOSell150,000$14.04$2,106,000.00View SEC Filing  
5/27/2015Anne-Marie Juliette RipleyVPSell45,629$13.04$595,002.16View SEC Filing  
3/23/2015Robert J GreenbergCEOSell100,000$13.28$1,328,000.00View SEC Filing  
11/19/2014Gregg WilliamsDirectorBuy111,111$9.00$999,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Second Sight Medical (NASDAQ EYES) News Headlines

Source:
DateHeadline
Second Sight Medical (EYES) Set to Announce Quarterly Earnings on TuesdaySecond Sight Medical (EYES) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 24 at 8:24 AM
Second Sight Medical (EYES) vs. Edap Tms (EDAP) Head-To-Head AnalysisSecond Sight Medical (EYES) vs. Edap Tms (EDAP) Head-To-Head Analysis
www.americanbankingnews.com - April 17 at 5:37 PM
Second Sight Medical (EYES) Given a $5.00 Price Target by HC Wainwright AnalystsSecond Sight Medical (EYES) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 12 at 9:00 PM
Second Sight Medical (EYES) Announces Dr. Robert Greenbergs Resignation from Board of DirectorsSecond Sight Medical (EYES) Announces Dr. Robert Greenberg's Resignation from Board of Directors
www.streetinsider.com - April 10 at 10:53 AM
Second Sight Announces Dr. Robert Greenberg’s Resignation from Board of Directors and as an Officer of the CompanySecond Sight Announces Dr. Robert Greenberg’s Resignation from Board of Directors and as an Officer of the Company
finance.yahoo.com - April 10 at 10:53 AM
Second Sight Medical (EYES) PT Set at $5.00 by HC WainwrightSecond Sight Medical (EYES) PT Set at $5.00 by HC Wainwright
www.americanbankingnews.com - April 6 at 9:50 PM
Second Sight Medical (EYES) Downgraded by Zacks Investment ResearchSecond Sight Medical (EYES) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 31 at 4:56 PM
HC Wainwright Reiterates "$5.00" Price Target for Second Sight Medical Products (EYES)HC Wainwright Reiterates "$5.00" Price Target for Second Sight Medical Products (EYES)
www.americanbankingnews.com - March 25 at 11:41 AM
Second Sight Medical (EYES) Names John T. Blake as Chief Financial Officer - StreetInsider.comSecond Sight Medical (EYES) Names John T. Blake as Chief Financial Officer - StreetInsider.com
www.streetinsider.com - March 22 at 3:51 PM
Second Sight Medical (EYES) Names Gregg Williams to Board - StreetInsider.comSecond Sight Medical (EYES) Names Gregg Williams to Board - StreetInsider.com
www.streetinsider.com - March 16 at 3:39 PM
Second Sight Medical (EYES) Names Gregg Williams to BoardSecond Sight Medical (EYES) Names Gregg Williams to Board
www.streetinsider.com - March 16 at 11:34 AM
Second Sight Appoints Gregg Williams as Chairman of the Board of DirectorsSecond Sight Appoints Gregg Williams as Chairman of the Board of Directors
finance.yahoo.com - March 16 at 11:34 AM
Second Sight Medical Products, Inc. to Present at the B. Riley & Co. China Healthcare Investment Partnering SymposiumSecond Sight Medical Products, Inc. to Present at the B. Riley & Co. China Healthcare Investment Partnering Symposium
finance.yahoo.com - March 9 at 10:41 AM
Second Sight Medical Products (EYES) CEO Will McGuire on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaSecond Sight Medical Products' (EYES) CEO Will McGuire on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 8 at 3:40 PM
Second Sight Reports Fourth Quarter and Full Year 2017 Financial ResultsSecond Sight Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 8 at 10:45 AM
Second Sight Medical Products (EYES) Announces  Earnings ResultsSecond Sight Medical Products (EYES) Announces Earnings Results
www.americanbankingnews.com - March 7 at 9:14 PM
Second Sight Medical Products, Inc. to Host Earnings CallSecond Sight Medical Products, Inc. to Host Earnings Call
finance.yahoo.com - March 7 at 3:38 PM
Second Sight Medical (EYES) Reports Expansion of Medicare ... - StreetInsider.comSecond Sight Medical (EYES) Reports Expansion of Medicare ... - StreetInsider.com
www.streetinsider.com - March 6 at 3:35 PM
Second Sight Medical (EYES) Reports Expansion of Medicare Coverage for Argus II Retinal ProsthesisSecond Sight Medical (EYES) Reports Expansion of Medicare Coverage for Argus II Retinal Prosthesis
www.streetinsider.com - March 6 at 10:52 AM
Second Sight Announces Latest Expansion of Medicare Coverage for Argus II Retinal Prosthesis SystemSecond Sight Announces Latest Expansion of Medicare Coverage for Argus II Retinal Prosthesis System
finance.yahoo.com - March 6 at 10:51 AM
Second Sight Medical Products, Inc. to Present at the Inaugural LD ... - Business Wire (press release)Second Sight Medical Products, Inc. to Present at the Inaugural LD ... - Business Wire (press release)
www.businesswire.com - March 5 at 3:46 PM
Second Sight Medical Products, Inc. to Present at the Inaugural LD Micro Virtual Investor Conference on March 7, 2018Second Sight Medical Products, Inc. to Present at the Inaugural LD Micro Virtual Investor Conference on March 7, 2018
finance.yahoo.com - March 5 at 11:14 AM
Second Sight to Discuss Fourth Quarter and Year-End 2017 Financial Results on March 7, 2018 Conference CallSecond Sight to Discuss Fourth Quarter and Year-End 2017 Financial Results on March 7, 2018 Conference Call
finance.yahoo.com - February 28 at 10:52 AM
Second Sight Medical Products (EYES) to Release Earnings on WednesdaySecond Sight Medical Products (EYES) to Release Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:58 AM
Second Sight Medical (EYES) Gains Following Entry into Singapore - StreetInsider.comSecond Sight Medical (EYES) Gains Following Entry into Singapore - StreetInsider.com
www.streetinsider.com - February 17 at 3:37 PM
Second Sight Announces Market Entry into Singapore with First Implant of Argus II Retinal Prosthesis SystemSecond Sight Announces Market Entry into Singapore with First Implant of Argus II Retinal Prosthesis System
finance.yahoo.com - February 16 at 9:59 AM
Second Sight Medical Products (EYES) vs. Amedica (AMDA) Head-To-Head ReviewSecond Sight Medical Products (EYES) vs. Amedica (AMDA) Head-To-Head Review
www.americanbankingnews.com - February 15 at 12:46 PM
First Look At Second Sight - Seeking AlphaFirst Look At Second Sight - Seeking Alpha
seekingalpha.com - February 8 at 5:16 AM
Second Sight Medical, Investors Open Their Eyes Making These Shares Soar, Recent DevelopmentsSecond Sight Medical, Investors Open Their Eyes Making These Shares Soar, Recent Developments
finance.yahoo.com - February 8 at 5:16 AM
Second Sight (EYES) Catches Eye: Stock Jumps 12.7% - NasdaqSecond Sight (EYES) Catches Eye: Stock Jumps 12.7% - Nasdaq
www.nasdaq.com - February 6 at 3:17 PM
Second Sight (EYES) Catches Eye: Stock Jumps 12.7%Second Sight (EYES) Catches Eye: Stock Jumps 12.7%
finance.yahoo.com - February 6 at 3:17 PM
Second Sight Medical Products Inc Execution Is Firing on All Cylinders Following Standout 4Q:17 ImplantsSecond Sight Medical Products Inc Execution Is Firing on All Cylinders Following Standout 4Q:17 Implants
finance.yahoo.com - February 6 at 3:17 PM
33 Biggest Movers From Yesterday - Benzinga33 Biggest Movers From Yesterday - Benzinga
www.benzinga.com - February 6 at 5:25 AM
31 Stocks Moving In Mondays Mid-Day Session | Benzinga - Benzinga31 Stocks Moving In Monday's Mid-Day Session | Benzinga - Benzinga
www.benzinga.com - February 6 at 5:25 AM
Pre-Open Movers 02/05: (CAPR) (EYES) (BG) Higher; (WFC) (DKS) (QCOM) Lower (more...) - StreetInsider.comPre-Open Movers 02/05: (CAPR) (EYES) (BG) Higher; (WFC) (DKS) (QCOM) Lower (more...) - StreetInsider.com
www.streetinsider.com - February 5 at 3:17 PM
Mid-Afternoon Market Update: Dow Tumbles Over 400 Points; Crude Oil Down 2% - BenzingaMid-Afternoon Market Update: Dow Tumbles Over 400 Points; Crude Oil Down 2% - Benzinga
www.benzinga.com - February 5 at 3:17 PM
Second Sight Medical (EYES) Provides Update on Key Performance Metrics - StreetInsider.comSecond Sight Medical (EYES) Provides Update on Key Performance Metrics - StreetInsider.com
www.streetinsider.com - February 5 at 3:17 PM
Second Sight Announces Record Number of Argus II Retinal Prosthesis Systems Implants and Completes First-in-Human Orion Cortical ImplantSecond Sight Announces Record Number of Argus II Retinal Prosthesis Systems Implants and Completes First-in-Human Orion Cortical Implant
finance.yahoo.com - February 5 at 3:17 PM
 Second Sight Medical Products Inc (EYES) Given $5.00 Consensus Target Price by Analysts Second Sight Medical Products Inc (EYES) Given $5.00 Consensus Target Price by Analysts
www.americanbankingnews.com - February 3 at 3:22 PM
Pre-Market Technical Scan on Medical Equipment Equities -- Senseonics, Aethlon Medical, CHF Solutions, and ... - PR Newswire (press release)Pre-Market Technical Scan on Medical Equipment Equities -- Senseonics, Aethlon Medical, CHF Solutions, and ... - PR Newswire (press release)
www.prnewswire.com - January 22 at 7:45 AM
Zacks: Analysts Set $5.00 Price Target for Second Sight Medical Products Inc (EYES)Zacks: Analysts Set $5.00 Price Target for Second Sight Medical Products Inc (EYES)
www.americanbankingnews.com - January 22 at 1:20 AM
Second Sight Medical Products (EYES) Raised to Hold at Zacks Investment ResearchSecond Sight Medical Products (EYES) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - January 8 at 11:30 PM
January Growth Opportunities – Athenex And MoreJanuary Growth Opportunities – Athenex And More
finance.yahoo.com - December 31 at 5:05 PM
Comparing Second Sight Medical Products (EYES) & Its RivalsComparing Second Sight Medical Products (EYES) & Its Rivals
www.americanbankingnews.com - December 22 at 9:20 PM
Second Sight Medical Products (EYES) & Its Competitors Head-To-Head ReviewSecond Sight Medical Products (EYES) & Its Competitors Head-To-Head Review
www.americanbankingnews.com - December 20 at 9:32 AM
Second Sight Medical Products (EYES) vs. Its Rivals Head-To-Head ComparisonSecond Sight Medical Products (EYES) vs. Its Rivals Head-To-Head Comparison
www.americanbankingnews.com - December 19 at 3:26 PM
Critical Review: Second Sight Medical Products (EYES) versus The CompetitionCritical Review: Second Sight Medical Products (EYES) versus The Competition
www.americanbankingnews.com - December 19 at 9:32 AM
Zacks: Second Sight Medical Products, Inc. (EYES) Given $5.00 Average Target Price by BrokeragesZacks: Second Sight Medical Products, Inc. (EYES) Given $5.00 Average Target Price by Brokerages
www.americanbankingnews.com - December 18 at 3:28 PM
Second Sight Medical Products (EYES) versus Its Competitors Critical AnalysisSecond Sight Medical Products (EYES) versus Its Competitors Critical Analysis
www.americanbankingnews.com - December 17 at 1:28 AM
Second Sight Medical Products (EYES) & Its Rivals Financial ReviewSecond Sight Medical Products (EYES) & Its Rivals Financial Review
www.americanbankingnews.com - December 15 at 9:14 AM

SEC Filings

Second Sight Medical (NASDAQ:EYES) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Second Sight Medical (NASDAQ:EYES) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Second Sight Medical (NASDAQ EYES) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.